| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2093589 | Stem Cell Reports | 2014 | 8 Pages |
•Transplantation of human iPSC-derived cells to spinal cord of ALS model mice•Transplanted glial-rich NPCs attenuated non-cell autonomous neurodegeneration•Feasibility study for ALS transplantation is presented
SummaryTransplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source.
Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide
